Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
OREX > SEC Filings for OREX > Form 8-K on 30-Nov-2012All Recent SEC Filings

Show all filings for OREXIGEN THERAPEUTICS, INC. | Request a Trial to NEW EDGAR Online Pro

Form 8-K for OREXIGEN THERAPEUTICS, INC.


30-Nov-2012

Change in Directors or Principal Officers


Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On November 29, 2012, the board of directors (the "Board") of Orexigen Therapeutics, Inc. (the "Company"), pursuant to the Company's bylaws, voted to
(1) increase the size of the Board from eight to nine members and (2) appoint David Endicott to the Board to fill the vacancy created by the increase. Mr. Endicott was appointed as a Class III director, with an initial term expiring at the Company's 2013 annual meeting of stockholders. This appointment by the Board was based on the recommendation of its nominating/corporate governance committee. Mr. Endicott has been determined by the Board to be independent within the meaning of the independent director standards of the Securities and Exchange Commission and the Nasdaq Stock Market, Inc.

In connection with Mr. Endicott's appointment to the Board, he will be entitled to receive compensation consistent with that of the Company's other non-employee directors under the Company's Independent Director Compensation Policy, as such policy may be amended from time to time. In accordance with the Independent Director Compensation Policy, Mr. Endicott has been granted an option to purchase 35,000 shares of the Company's common stock and cash compensation in the amount of $35,000 per year for his service as a director.

There are no arrangements or understandings between Mr. Endicott and any other person pursuant to which he was selected to serve on the Board. There are no transactions in which the Company is a party and in which Mr. Endicott has a material interest subject to disclosure under Item 404(a) of Regulation S-K.


  Add OREX to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for OREX - All Recent SEC Filings
Sign Up for a Free Trial to the NEW EDGAR Online Pro
Detailed SEC, Financial, Ownership and Offering Data on over 12,000 U.S. Public Companies.
Actionable and easy-to-use with searching, alerting, downloading and more.
Request a Trial      Sign Up Now


Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.